

2026 ITOX Symposium

Poster Presentations

Clinical Research

“Contraindicated or not? Rechallenging with immune checkpoint inhibitors after neurological immune-related adverse events in immunogenic solid tumors”

Ali-Musa Jaffer, MD, Assistant Professor, Neuro-Oncology, University of Florida-Jacksonville, Moffit Cancer Center

“Neurological immune-related adverse events from immune checkpoint inhibitors in lung cancer: Earlier, harsher, and harder to rechallenge”

Husayn Jaffer, Undergraduate Student, Neuro-Oncology, University of Florida-Jacksonville, Moffit Cancer Center

“Efficacy and safety of infliximab for management of immune-related adverse events (irAEs): A retrospective multi-irAE analysis”

Anirudha Chatterjee, MD, Resident, Internal Medicine, UT Medical Branch at Galveston

“The four Ms of the apocalypse: A case study of nivolumab-induced triple M overlap syndrome (myocarditis, myositis, myasthenia) and mortality and the subsequent impact on palliative care”

Aryan Dowlatshahi, MD, Fellow, Palliative Care Medicine, UT MD Anderson Cancer Center

“Retreatment in patients with neurologic immune-related adverse events”

Clara Baselga-Garriga, Resident, Massachusetts General Hospital

“Real world utilization of irAE ICD-10 codes using a national database”

Benjamin Yaniv, MD, Assistant Professor, Hospital Medicine, University of Massachusetts Chan Medical School

“LLM-assisted balanced screening for pre-severe immunotherapy complication (SIC) triage in inpatient oncology admissions”

Bingyang Ye, PhD, Postdoctoral Fellow, Radiation Oncology, Brigham and Women's Hospital

“Seasons of risk: Investigating temporal trends in ICI-associated myocarditis”

Crystal Griffith, Medical Student, Howard University College of Medicine

“Case report: Steroid-refractory immune checkpoint inhibitor-associated myocarditis and myositis requiring sequential immunosuppression”

Darcie Kim, Research Assistant, Harvard Stem Cell and Regenerative Biology, Massachusetts General Hospital

2026 ITOX Symposium Poster Presentations

Clinical Research

“Reporting symptoms of potential immune-related adverse events in people with cancer treated with checkpoint inhibitors: A qualitative examination of patient perceptions in the INSITE study”

Deanne Tibbitts, PhD, Assistant Professor, Oncological Sciences, Knight Cancer Institute at Oregon Health and Science University

“Antibody-drug conjugate associated pneumonitis (AAP) across novel first-in-human phase I trials: A pooled single-center analysis”

Fayaz Falah, MD, Associate Research Scholar, Oklahoma University Health Stephenson Cancer Center

“Incidence And Risk Factors For Pneumonitis After Check Point Inhibitor Immunotherapy In Patients With Genitourinary Cancers”

Fernando Camacho, MD, Rotating Fellow, Pulmonary Medicine, UT MD Anderson

“Analysis of patient reported outcomes and ambulatory spirometry ability to detect pneumonitis”

Gregory Gaskey, MD, Fellow, Pulmonary and Critical Care Medicine, UTHealth Houston McGovern Medical School

“Treatment of refractory immune checkpoint inhibitor-mediated hepatobiliary toxicity with IL-2R-alpha blockade/anti-CD25: A case study”

Hao Chi Zhang, MD, Assistant Professor, Gastroenterology & Hepatology, UT MD Anderson

“Humoral and cellular immune perturbations in immune checkpoint inhibitor-related myositis and myocarditis”

Hong Mu-Mosley, MD, PhD, Clinical Research Coordinator Lead, Biomarker Research Laboratory, UT Southwestern Medical Center

“Extraintestinal immune-related adverse events in patients with inflammatory bowel diseases treated with immune checkpoint inhibitors”

Humberto Nieves Jiménez, MD, Rotating Resident, Internal Medicine Education Program, UT MD Anderson

“Clinical characteristics and outcomes of immune-related adverse events in a safety-net hospital: A retrospective single-center study”

Jaewon Lee, MD, Resident, Internal Medicine, University of Massachusetts Chan Medical School

2026 ITOX Symposium

Poster Presentations

Clinical Research

“Fulminant multi-organ dysfunction after ipilimumab/nivolumab with meningoencephalitis”

James Sullivan, MD, Resident, Internal Medicine, Mass General Brigham

“Creation of an expedited rheumatology-oncology clinic: Utilization and appointment wait times”

Julia Chernis, MD, Fellow, Rheumatology, University of Colorado Denver Anschutz Medical Campus

“Immunotherapy Toxicity Operational Platform (ITOP): An institutional, multi-level approach resource that enables longitudinal immune checkpoint inhibitor-related toxicity (ITOX) research”

Keila Ostos Mendoza, MD, Postdoctoral Fellow, Cardiology, UT MD Anderson

“Infliximab for steroid-refractory immune checkpoint inhibitor-associated nephritis: A case series”

Leyre Zubiri, MD, PhD, Instructor, Massachusetts General Hospital

“Pregnancy outcomes following immune checkpoint inhibitor exposure”

Magdalena Fay, MD, Resident, Internal Medicine Resident, Massachusetts General Hospital

“Severe immune-related adverse events in the neoadjuvant and adjuvant setting: Insights from the MGH severe immunotherapy complications database”

Malini Gandhi, MD, Resident Physician, Internal Medicine, Brigham and Women’s Hospital

“Oral immune-related adverse events associated with immune checkpoint inhibitors: Clinical implications for multidisciplinary care”

Maria Fernanda Garza, DDS, Researcher, Oral and Maxillofacial Surgery, Universidad Autónoma De Nuevo León

“Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis: A report of two cases highlighting diagnostic challenges”

Mayté Martínez Garza, Visiting Medical Student, Hematology, UT MD Anderson

“Risk factors associated to VTE in lung cancer treated with immune checkpoint inhibitors”

Cristhiam M. Rojas Hernandez, MD, Associate Professor, Hematology, UT MD Anderson

“Process-adherent transaminitis evaluation leading to incidental detection of smoldering immune checkpoint inhibitor-associated myocarditis”

Mikaela Enax, Clinical Research Coordinator, UMass Chan School of Medicine

2026 ITOX Symposium

Poster Presentations

Clinical Research

“Hospitalization patterns and evolving inpatient management of immune checkpoint inhibitor-associated colitis”

Nadia Kirmani, Medical Student, Stanford University School of Medicine

“Expanding the role of IL-23 inhibitors: Efficacy and safety in immune-related adverse events”

Nina Quirk, MD, Resident, Internal Medicine, McGovern Medical School at UTHealth Houston

“C-peptide kinetics following immune checkpoint inhibitor diabetes diagnosis”

Zoe Quandt, MD, Assistant Professor, Endocrinology, University of California, San Francisco

“Hypomotility of lower gastrointestinal tract post immune checkpoint inhibitors”

Raakhi Menon, DO, Chief Resident, Internal Medicine, UTMB

“Respiratory failure in patients treated with immune checkpoint inhibitors”

Aliyah Pabani MD, Assistant Professor of Oncology, Upper Aerodigestive Cancer Division, Sidney Kimmel Comprehensive Cancer at Johns Hopkins University

“Operational feasibility of centralized remote nursing triage for toxicity monitoring”

Sarah Shaker, MD, Rotating Resident, Cancer Medicine, Fellowship Program, UT MD Anderson

“Normal on the surface, turbulent beneath: A new histologic view of ICI-associated microscopic colitis”

Sean Ngo, MD, Resident, Internal Medicine, McGovern Medical School at UTHealth Houston

“AI-assisted identification and clinical outcomes of CAR-T induced immune effector cell-associated hemophagocytic syndrome (IEC-HS) across hematologic and solid malignancies”

Suyang Wang, Graduate Student Researcher, Epidemiology & Biostatistics, University of California, San Francisco

“Immune-related adverse events in people living with HIV receiving immune checkpoint inhibitors for advanced malignancy”

Sydney Corey, Medical Student, Harvard Medical School

“Early colon adenoma development following immune checkpoint inhibitor-mediated diarrhea and colitis”

Tanvi Gupta, MD, Chief Medical Resident and Clinical Instructor, Internal Medicine, McGovern Medical School at UTHealth Houston

“Raynaud’s phenomenon in the setting of immune checkpoint inhibitors: A case series and possible implications”

Yuanteng Jeff Li, MD, Assistant Professor, Rheumatology, UT MD Anderson

2026 IOTOX Symposium Poster Presentations

Basic/Translational Science

“Immune cell migration and function in immune checkpoint induced autoimmune diabetes”

Arielle Dessens, PhD, Postdoctoral Fellow, Immunology, UT MD Anderson

“Immune alterations associated with immunotherapy: An expanding biobanking study”

Elizabeth Park, Life Science Research Professional, Division of Oncology, Stanford University School of Medicine

“Investigating the role of allelic imbalance in pancreatic cancer aggressiveness, survival, and therapeutic resistance”

Enrico Gurreri, MD, Postdoctoral Fellow, Genitourinary Medical Oncology, Research, UT MD Anderson

“Predictive biomarkers and conceptual risk stratification of immune-related gastrointestinal adverse events in patients receiving immune checkpoint inhibitors”

Jorge Gonzalez, Medical Student, Universidad Anáhuac México

“Alternate-day fasting reduces immune-related colitis in a murine model”

Michelle Ferreira, MD, Postdoctoral Fellow, Medical Oncology, Sidney Kimmel Comprehensive Cancer at Johns Hopkins University

“Lower lobe and total lung quantitative fibrosis scores identified by quantitative CT predict pneumonitis risk in non-small cell lung cancer (NSCLC)”

Mitchell Boshkos, DO, Rotating Medicine, Internal Medicine Education Program, UT MD Anderson

“Single-cell multi-omic profiling uncovers tissue and circulating signatures of immune-mediated liver injury from checkpoint inhibitors”

Molly Thomas, MD, PhD, Assistant Professor, Gerontology & Hepatology, Oregon Health & Science University and Massachusetts General Hospital

“Disentangling protective anti-tumor responses from autoimmune toxicities following checkpoint blockade in melanoma”

Rachel Morris, Graduate Research Assistant, Immunology, UT MD Anderson

2026 IOTOX Symposium Poster Presentations

Basic/Translational Science

“Turning Clinical Complexity into Discovery: A Translational Program for Immune-Related Adverse Events”

Roya Best, Research Associate, Massachusetts General Hospital and Broad Institute of Massachusetts Institute of Technology and Harvard University

“Ferroptotic vulnerabilities in M1 and M2 macrophages as a driver of adaptive radiation resistance in esophageal adenocarcinoma”

Sadhna Aggarwal, PhD, Postdoctoral Fellow, Thoracic Radiation Oncology, UT MD Anderson

“Multi-modality data analysis identifies predictive gene signatures of immune checkpoint blockade toxicity”

Yang Liu, PhD, Research Scientist, O'Donnell School of Public Health, UT Southwestern Medical Center

“A multi-agent large language model framework for automated detection of immune-related adverse event onset from longitudinal electronic health records”

Yuansheng Zhang, PhD, Postdoctoral Researcher, Brigham and Women's Hospital